

Exhibit 99.1



Third Quarter 2008 Webcast

October 23, 2008

Alcon[®]

Safe Harbor Statement

This presentation, made on October 23, 2008, includes forward-looking statements based on current expectations and Alcon does not undertake the obligation to update the forward-looking information or statements. These expectations could differ materially from actual results and are subject to a number of uncertainties and risks as detailed in the company's form 20-F filed with the SEC on March 18, 2008.

In addition, this presentation may include several financial measures, to assist in better understanding our business, that are not prepared in accordance with generally accepted accounting principles (GAAP). These non-GAAP financial measures will be reconciled at the end of this presentation or in associated public information filed with the SEC.

Reports noted above are available on our website at www.alcon.com in the "Investors and Media" section. For further information contact the Alcon Investor Relations Department at (817)551-8805.


Business Overview

Cary Rayment
Chairman, President & CEO

Third Quarter Sales Highlights

3rd Qtr

(dollars in millions)



September 2008 YTD


(dollars in millions)



* Constant currency sales growth is a non-GAAP measure presented to give investors a better comparison of operations between years. Reconciliations for constant currency are provided in slides at the end of this presentation.

Q3 2008 Geographic Sales and Growth



Q3 2008 Sales by Geography



* Constant currency sales growth is a non-GAAP measure presented to give investors a better comparison of operations between years. Reconciliations for constant currency are provided in slides at the end of this presentation.

Pharmaceutical Sales

Q3 2008 Sales by Product Line



* Constant currency sales growth is a non-GAAP measure presented to give investors a better comparison of operations between years. Reconciliations for constant currency are provided in slides at the end of this presentation.

Gaining Market Share in Pharmaceuticals

<u>RX Growth</u>	Global June YTD		US August YTD		US August 2008
	Brand	Market	Brand	Market	Market
TRAVATAN® Family	16.3%	8.3%	12.4%	-1.2%	-6.7%
Azopt®	7.7%	6.1%	16.6%	4.3%	-5.1%
Vigamox® *	20.6%	7.7%	-2.5%	-4.6%	-11.1%
TobraDex®	6.8%	7.4%	-8.3%	-4.7%	-10.9%
NEVANAC®	62.2%	3.4%	21.6%	9.6%	2.5%
Patanol® + Pataday™	23.1%	2.3%	-3.1%	-8.9%	-12.1%
CIPRODEX® *	7.4%	0.3%	11.1%	1.8%	-12.1%

* Moxifloxacin, the active ingredient in **Vigamox®**, is licensed to Alcon by Bayer HealthCare AG.
CIPRODEX® is a registered trademark of Bayer AG and licensed to Alcon by Bayer HealthCare AG.


Source: Global-IMS US-WK Health

Alcon®

Alcon Glaucoma Strength


Alcon Global Prostaglandin Market Share

TRAVATAN® Family revenues up 20.2% for Q3 2008



U.S. Rx Share of TRAVATAN Z® as a Percentage of the Total TRAVATAN® Franchise


TRAVATAN® Franchise is up 6.3 share points since TRAVATAN Z® launch



Strong Share Gains from Azopt®

Global TCAI Market Share Development

Azopt® revenues up 19.9% for Q3 2008





* Trusopt is a registered trademark of Merck.

Source: IMS

Surgical Sales


Q3 2008 Sales by Product Line




* Constant currency sales growth is a non-GAAP measure presented to give investors a better comparison of operations between years. Reconciliations for constant currency are provided in slides at the end of this presentation.

Alcon Monofocal IOLs are Growing Share

U.S. Monofocal IOL Market Shares




Advanced Technology IOL Sales Trend




Cataract Procedure and Viscoelastic Share Growth

U.S. Phaco Machine Share




U.S. Viscoelastics Share




Consumer Sales

Q3 2008 Sales by Product Line




3rd Qtr (dollars in millions)



* Constant currency sales growth is a non-GAAP measure presented to give investors a better comparison of operations between years. Reconciliations for constant currency are provided in slides at the end of this presentation.


Contact Lens Care Market Share Success

U.S. Contact Lens Care Market Share (including Private Label)



Impact of Systane® on Dry Eye Revenue

Global Dollar Sales by Quarter of Dry Eye Products



Financial Review


Rick Croarkin

Senior Vice President, Finance and Chief Financial Officer

Q3 Gross Profit


3rd Qtr

(dollars in millions)



September 2008 YTD

(dollars in millions)




Q3 Operating Profit

3rd Qtr

(dollars in millions)

+6.1%



% of
Sales


34.9%

32.4%

September 2008 YTD

(dollars in millions)

+16.7%



% of
Sales


34.0%

34.2%

Q3 Net Earnings

3rd Qtr

(dollars in millions)




% of
Sales

31.1%

41.1%

September 2008 YTD

(dollars in millions)



% of
Sales


29.3%

33.8%

Alcon Investment Portfolio Allocation

Investment Allocation at Q3 2008

\$3.12 Billion Portfolio



Alcon Historical Investment Performance


<i>(dollars in millions)</i>	FY 2004	FY 2005	FY 2006	FY 2007	Q1 2008	Q2 2008	Q3 2008	YTD 2008
Interest Income	\$23.3	\$48.7	\$74.1	\$69.3	\$25.7	\$20.5	\$19.8	\$66.0
Investment/ Other	(\$ 0.3)	\$ 4.4	\$21.2	\$15.4	(\$11.7)	\$ 0.5	(\$43.2)	(\$54.4)
Net Investment Income	\$23.0	\$53.1	\$95.3	\$84.7	\$14.0	\$21.0	(\$23.4)	\$11.6
Portfolio Yield (P&L)	1.9%	3.3%	4.9%	3.6%	0.5%	0.7%	(0.8%)	0.4%

Q3 Income Taxes

- \$239.5 million Summit Autonomous tax benefit resulted in total tax benefit of \$177.6 million
- Taxes on operations totaled \$61.9 million
- Shared Service Center tax benefit reduced the overall tax rate
- YTD Q3 2008 tax rate was 13.7% excluding the Summit Autonomous tax benefit vs. 16.5% in the same period in 2007
- R&D tax credit passed in October, so Q4 effective tax rate will likely be in the 11-12% range

Q3 Diluted EPS

3rd Qtr



September 2008 YTD



2008 Full Year Financial Guidance Revision

- Sales range of \$6,260 to \$6,290 million
- Diluted earnings per share range of \$6.67 to \$6.75
- The guidance includes:
 - Summit Autonomous tax benefits
 - Benefits from the R&D tax credit
 - Tax savings and costs to establish Shared Service Centers
 - Integration of refractive operations



Alcon®

Non-GAAP Constant Currency Reconciliation

(dollars in millions)	Q3 GAAP Growth Rate	Exchange Rate Changes	Q3 Constant Currency Growth Rate
Global Sales	14.1%	(3.8)	10.3%
Pharmaceutical	11.4%	(3.6)	7.8%
Surgical	18.0	(4.3)	13.7
Consumer	10.5	(3.5)	7.0
United States	4.1%	--	4.1%
Developed International	21.7	(7.4)	14.3
Emerging Markets	27.8	(8.0)	19.8
(dollars in millions)	YTD GAAP Growth Rate	Exchange Rate Changes	YTD Constant Currency Growth Rate

Global Sales	16.1%	(5.8)	10.3%
--------------	-------	-------	-------

Note: Constant Currency Growth Rate calculates sales growth without the impact of foreign exchange fluctuations. Management believes constant currency sales growth is an important measure of the company's operations because it provides investors with a clearer picture of the core rate of sales growth due to changes in unit volumes and local currency prices. This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission. Certain reclassifications have been made to prior year amounts to conform with current year presentation.